Filing Details
SUTRO BIOPHARMA, INC. (NASDAQ:STRO) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
8k filedNASDAQ:STRO
SUTRO BIOPHARMA, INC. (STRO) Reports Material Event to SEC
SUTRO BIOPHARMA, INC. (NASDAQ:STRO) filed a Form 8-K with the Securities and Exchange Commission on August 12, 2026, disclosing a material event.
At publication ·
What changed
SUTRO BIOPHARMA, INC. (NASDAQ:STRO) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Sutro Biopharma filed a Form 8-K with the SEC on August 12, 2026, disclosing a material event that shareholders should be aware of, though the specific nature of the event is not detailed in this filing notice.
- The company's stock trades at $21.30 with a market capitalization of $83.5 million as of the filing date.
- Form 8-K filings are used to report material events such as leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
SUTRO BIOPHARMA, INC.'s stock currently trades at $21.30 with a market capitalization of $83.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for SUTRO BIOPHARMA, INC.'s stock.
All SEC filings for SUTRO BIOPHARMA, INC. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View STRO Stock Page
Frequently Asked Questions
Where can I read STRO's SEC filings?
Browse all filings on our STRO SEC filings page.
What types of SEC filings does SUTRO BIOPHARMA, INC. file?
Public companies like SUTRO BIOPHARMA, INC. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.